Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 5/2011

Ausgabe 5/2011

Inhaltsverzeichnis ( 48 Artikel )

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO

Steven Hutchens, Yefim Manevich, Lin He, Kenneth D. Tew, Danyelle M. Townsend

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity

Jérôme Devy, Farid Ouchani, Christelle Oudot, Jean Jacques Helesbeux, Enguerran Vanquelef, Stéphanie Salesse, Fanja Rabenoelina, Siana Al-Khara, Isabelle Letinois, Olivier Duval, Laurent Martiny, Emmanuelle Charpentier

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes

Georgi Momekov, Margarita Karaivanova, Iva Ugrinova, Evdokia Pasheva, Galina Gencheva, Daniela Tsekova, Sonia Arpadjan, Panayot R. Bontchev

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells

Norma O’Donovan, Annette T. Byrne, Aisling E. O’Connor, Sharon McGee, William M. Gallagher, John Crown

01.10.2011 | Preclinical Studies | Ausgabe 5/2011

An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities

Julio Benites, Jaime A. Valderrama, Henryk Taper, Pedro Buc Calderon

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011 Open Access

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

Roos L. Oostendorp, T. Buckle, G. Lambert, J. S. Garrigue, J. H. Beijnen, J. H. M. Schellens, O. van Tellingen

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis

Esther A. Guzmán, Jacob D. Johnson, Patricia A. Linley, Sarath E. Gunasekera, Amy E. Wright

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis

Danqing Xu, Ji Cao, Shijing Qian, Lin Li, Chunqi Hu, Qinjie Weng, Jianshu Lou, Difeng Zhu, Hong Zhu, Yongzhou Hu, Qiaojun He, Bo Yang

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα

Min Gui, Da-Kuo Shi, Min Huang, Yu Zhao, Qi-Ming Sun, Jing Zhang, Qin Chen, Jian-Ming Feng, Chun-Hong Liu, Ming Li, Ying-Xia Li, MeiYu Geng, Jian Ding

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity

Pere Tubert, Montserrat Rodríguez, Marc Ribó, Antoni Benito, Maria Vilanova

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

Alfonso Quintás-Cardama, Taghi Manshouri, Zeev Estrov, David Harris, Ying Zhang, Amos Gaikwad, Hagop M. Kantarjian, Srdan Verstovsek

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line

Yukako Fukushi, Masaharu Hazawa, Kenji Takahashi, Atsushi Yoshizawa, Ikuo Kashiwakura

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain

Meaghan MacPhee, Zakaria Rachid, Margarita Todorova, Qiyu Qiu, Gina Belinsky, Bertrand J. Jean-Claude

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis

Piotr Jasinski, Pawel Zwolak, Rachel Isaksson Vogel, Vidya Bodempudi, Kaoru Terai, Jorge Galvez, David Land, Arkadiusz Z. Dudek

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells

Bo-Kyung Kim, Dong-Myung Kim, Kyung-Sook Chung, Song-Kyu Park, Shin-Jung Choi, Alexander Song, Kiho Lee, Chang-Woo Lee, Kyung-Bin Song, Gyoonhee Han, Julian Simon, Hwan Mook Kim, Misun Won

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice

Jin-Bin Jia, Wen-Quan Wang, Hui-Chuan Sun, Liang Liu, Xiao-Dong Zhu, Ling-Qun Kong, Zong-Tao Chai, Wei Zhang, Ju-Bo Zhang, Hua-Xiang Xu, Zhao-Chong Zeng, Wei-Zhong Wu, Lu Wang, Zhao-You Tang

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution

M. S. Shahabuddin, Mridula Nambiar, Gopal M. Advirao, Sathees C. Raghavan

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity

In Hae Park, Jin Young Kim, Ji Young Choi, Ji-Youn Han

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study

Raphaël Beck, Rozangela Curi Pedrosa, Nicolas Dejeans, Christophe Glorieux, Philippe Levêque, Bernard Gallez, Henryk Taper, Stéphane Eeckhoudt, Laurent Knoops, Pedro Buc Calderon, Julien Verrax

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs

Pamela W. Lucas, Joanna M. Schmit, Quinn P. Peterson, Diana C. West, Danny C. Hsu, Chris J. Novotny, Levent Dirikolu, Mona I. Churchwell, Daniel R. Doerge, Laura D. Garrett, Paul J. Hergenrother, Timothy M. Fan

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration

Amel Dudakovic, Huaxiang Tong, Raymond J. Hohl

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor

Makiko Kobayashi, Ikuko Takahashi-Suzuki, Toshiyasu Shimomura, Yoshikazu Iwasawa, Hiroshi Hirai

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands

Beatriz Gallego, Milena R. Kaluđerović, Harish Kommera, Reinhard Paschke, Evamarie Hey-Hawkins, Torsten W. Remmerbach, Goran N. Kaluđerović, Santiago Gómez-Ruiz

01.10.2011 | PRECLINICAL STUDIES | Ausgabe 5/2011

Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin

Ki-Eun Hwang, Kyoung-Suk Na, Do-Sim Park, Keum-Ha Choi, Byoung-Ryun Kim, Hyeok Shim, Eun-Taik Jeong, Hak-Ryul Kim

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011 Open Access

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Neeltje Steeghs, Ron H. J. Mathijssen, Judith A. M. Wessels, Anne-Joy de Graan, Tahar van der Straaten, Mariangela Mariani, Bernard Laffranchi, Silvia Comis, Maja J. A. de Jonge, Hans Gelderblom, Henk-Jan Guchelaar

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Donald A. Richards, David Loesch, Svetislava J. Vukelja, Hillary Wu, William J. Hyman, Jeffery Nieves, Yunfei Wang, Simin Hu, Oluwatoyin O. Shonukan, Datchen F. Tai

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

Peter S. Galatin, Ranjana H. Advani, George A. Fisher, Brian Francisco, Thomas Julian, Raquel Losa, Marta I. Sierra, Branimir I. Sikic

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors

Hanna K. Sanoff, Janine M. Davies, Christine Walko, William Irvin, Larry Buie, Kimberly Keller, Anastasia Ivanova, Wing-Keung Chiu, Bert H. O’Neil, Thomas E. Stinchcombe, E. Claire Dees

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011 Open Access

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

Elena Soto, Ron J. Keizer, Iñaki F. Trocóniz, Alwin D. R. Huitema, Jos H. Beijnen, Jan H. M. Schellens, Jantien Wanders, Josep María Cendrós, Rosendo Obach, Concepción Peraire, Lena E. Friberg, Mats O. Karlsson

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

Benoit You, Anthony Brade, Joao M. Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David W. Hedley, Leonardo V. Nicacio, Eric X. Chen

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

Mark Andrew Dickson, Dana E. Rathkopf, Richard D. Carvajal, Steven Grant, John D. Roberts, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Robert A. Lefkowitz, Mithat Gonen, Lauren M. Cane, Heather J. Dials, Gary K. Schwartz

01.10.2011 | PHASE I STUDIES | Ausgabe 5/2011

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials

Som D. Mukherjee, Megan E. Coombes, Mitch Levine, Jarold Cosby, Brenda Kowaleski, Andrew Arnold

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, Katalin Boer, Antoine Adenis, Pilar Escudero, Tae-You Kim, Gillian M. Pover, Clive D. Morris, Jean-Yves Douillard

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Juan W. Valle, Anne Armstrong, Chris Newman, Valery Alakhov, Grzegorz Pietrzynski, Julie Brewer, Sue Campbell, Pippa Corrie, Eric K. Rowinsky, Malcolm Ranson

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

José María Viéitez, Manuel Valladares, Ignacio Peláez, Luis de Sande González, Jesús García-Foncillas, José Luis García-López, Carlos García-Girón, Margarita Reboredo, Humberto Bovio, Angel Jiménez Lacave

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

Srikala S. Sridhar, Eric Winquist, Andrea Eisen, Sebastien J. Hotte, Elaine McWhirter, Ian F. Tannock, Som D. Mukherjee, Lisa Wang, Chantale Blattler, John J. Wright, Malcolm J. Moore

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer

Sung Yong Oh, Young-Tae Ju, Sang-Kyung Choi, Chang Yoon Ha, Won Sup Lee, Hoon Gu Kim, Gyeong-Won Lee, Hyuk-Chan Kwon, Jung Hun Kang

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer

Colin D. Weekes, Sujatha Nallapareddy, Michelle A. Rudek, Alexis Norris-Kirby, Daniel Laheru, Antonio Jimeno, Ross C. Donehower, Kathleen M. Murphy, Manuel Hidalgo, Sharyn D. Baker, Wells A. Messersmith

01.10.2011 | Phase II Studies | Ausgabe 5/2011

Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness

Sung Yong Oh, Chi Young Jeong, Soon Chan Hong, Tae Hyo Kim, Chang Yoon Ha, Hyun Jin Kim, Gyeong-Won Lee, In Gyu Hwang, Joung Soon Jang, Hyuk-Chan Kwon, Jung Hun Kang

01.10.2011 | PHASE II STUDIES | Ausgabe 5/2011

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

Sang Joon Shin, Jae Heon Jeong, Young Suk Park, Kyung Hee Lee, Byoung Yong Shim, Tae Won Kim, Do Youn Oh, Myung Ah Lee, Yong Tai Kim, Yeul Hong Kim, Dae Young Zang, Jae Kyung Roh, Joong Bae Ahn

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer

Achillia Lakka, Ilias Mylonis, Sophia Bonanou, George Simos, Andreas Tsakalof

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

Romain Coriat, Stanislas Ropert, Olivier Mir, Bertrand Billemont, Stanislas Chaussade, Pierre-Philippe Massault, Benoit Blanchet, Olivier Vignaux, François Goldwasser

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

Stefan Faderl, Carlos Bueso-Ramos, Zhiming Liu, Ashutosh Pal, William Bornmann, Diana V. Ciurea, David Harris, Inbal Hazan-Halevy, Hagop M. Kantarjian, Zeev Estrov

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan

Moon Jin Kim, Gyeong-Won Lee, Jong Woo Seo, Hyun-Jung Kim, Sung-Nam Lim, Cheolwon Suh

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide

Catherine J. Drummond, Graeme J. Finlay, Laura Broome, Elaine S. Marshall, Emma Richardson, Bruce C. Baguley

01.10.2011 | SHORT REPORT | Ausgabe 5/2011

Ultraviolet recall dermatitis reaction with sorafenib

Nicolas Magné, Cyrus Chargari, Pierre Auberdiac, Coralie Moncharmont, Yacine Merrouche, Jean-Philippe Spano

01.10.2011 | REVIEW | Ausgabe 5/2011

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman, Patricia L. Myskowski

01.10.2011 | Erratum | Ausgabe 5/2011

Erratum to: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs

Joseph A. Bauer, Gerald Frye, Anne Bahr, Jennifer Gieg, Peter Brofman

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise